hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06288477, orgStudyIdInfo id: 2023-2, briefTitle: Clinical and Radiographic Evaluation of Vital Pulpotomy Techniques in Primary Molars Using of Premixed Bioactive Bioceramic MTA (Neo-putty) as a Novel Pulpotomy Medication Versus Formocresol, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2024-05-01, completionDateStruct date: 2025-02-01, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: October University for Modern Sciences and Arts, class: OTHER, descriptionModule briefSummary: Despite the benefit of formocresol, there are toxic effects allergic reactions and local soft and hard tissue necrosis have been reported when such formaldehyde compounds were used clinically, however, the adverse effect of the clinically used of this compound are not widely reported. It has been stated that it has a side effect on the permanent successor although it results as a successful technique for the treatment of the primary teeth, conditionsModule conditions: Vital, conditions: Pulpotomy, conditions: Techniques, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 44, type: ESTIMATED, armsInterventionsModule interventions name: A cotton pellet moistened with full-strength FC, interventions name: Neo-Putty, outcomesModule primaryOutcomes measure: Clinical success, eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 9 Years, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06288464, orgStudyIdInfo id: 315656, secondaryIdInfos id: 22/WM/0222, type: OTHER, domain: Health Research Authority, briefTitle: Enteral Feeding of Fibre to Improve Microbiota, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-09, primaryCompletionDateStruct date: 2025-12-01, completionDateStruct date: 2025-12-01, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Lancashire Teaching Hospitals NHS Foundation Trust, class: OTHER, collaborators name: Lancaster University, descriptionModule briefSummary: Following surgical removal of diseased bowel, patients often require a temporary redirection of bowel contents to a stoma, to allow healing prior to re-joining of the remaining bowel at a later date. Some patients may experience complications, either during or after reversal surgery, and this may be due to changes in the 'friendly' bacteria that live in our bowels. Previous research shows that the distal section of bowel that is non-functioning undergoes tissue-wasting and the 'friendly' bacteria that help our digestion die. Data shows that patients that have a reduction in their microflora are more likely to experience side effects. This study investigates a method of replenishing the microflora prior to surgery., conditionsModule conditions: Bowel Dysfunction, conditions: Colon Disease, conditions: Ileum--Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Cohort, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: Soluble Fibre, outcomesModule primaryOutcomes measure: Concentration of Microbiota, primaryOutcomes measure: Concentration of Immune Cell Populations, secondaryOutcomes measure: Length of Stay, secondaryOutcomes measure: Rate of clinical complications, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Lancashire Teaching Hospitals NHS, status: RECRUITING, city: Preston, state: Lancashire, zip: PR2 9HT, country: United Kingdom, contacts name: Kina Bennett, role: CONTACT, phone: (+44) 01772 522031, email: kina.bennett@lthtr.nhs.uk, contacts name: Research Access, role: CONTACT, email: research.access@lthtr.nhs.uk, contacts name: Arnab Bhowmick, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 53.76282, lon: -2.70452, documentSection largeDocumentModule largeDocs typeAbbrev: Prot, hasProtocol: True, hasSap: False, hasIcf: False, label: Study Protocol, date: 2023-02-01, uploadDate: 2024-02-23T12:17, filename: Prot_000.pdf, size: 250752, hasResults: False
protocolSection identificationModule nctId: NCT06288451, orgStudyIdInfo id: STUDY00018021, secondaryIdInfos id: 1K23DK136930-01, type: NIH, link: https://reporter.nih.gov/quickSearch/1K23DK136930-01, briefTitle: DePTH: De-emphasize PTH, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-11, primaryCompletionDateStruct date: 2027-02-28, completionDateStruct date: 2027-02-28, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: University of Washington, class: OTHER, collaborators name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), descriptionModule briefSummary: The De-emphasize Parathyroid Hormone (DePTH) Study is a 12-month pragmatic, randomized, parallel-group, active comparator, open-label, blinded end-point study of 90 patients with incident or prevalent secondary hyperparathyroidism and kidney failure treated with in-center hemodialysis. It tests the hypothesis that low fixed-dose oral calcitriol (intervention) will have more favorable effects on a comprehensive panel of biomarkers that assesses mineral metabolism, bone turnover, and serum calcification propensity, compared with variably-dosed intravenous activated vitamin D titrated to PTH targets (usual care)., conditionsModule conditions: Kidney Failure, Chronic, conditions: Chronic Kidney Disease-Mineral and Bone Disorder, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Oral calcitriol with cinacalcet rescue, interventions name: IV activated vitamin D, outcomesModule primaryOutcomes measure: Change in fibroblast growth factor-23, secondaryOutcomes measure: Change in serum calcium, secondaryOutcomes measure: Change in serum phosphate, secondaryOutcomes measure: Change in serum bone-specific alkaline phosphatase, secondaryOutcomes measure: Change in serum parathyroid hormone, secondaryOutcomes measure: Change in T50 test of serum calcification propensity, otherOutcomes measure: Patient acceptability, otherOutcomes measure: Patient acceptability, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Washington, status: RECRUITING, city: Seattle, state: Washington, zip: 98104, country: United States, contacts name: Simon Hsu, MD, MS, role: CONTACT, phone: 206-540-5714, email: sihsu@uw.edu, contacts name: Ian H de Boer, MD, MS, role: PRINCIPAL_INVESTIGATOR, contacts name: Simon Hsu, MD, MS, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 47.60621, lon: -122.33207, hasResults: False
protocolSection identificationModule nctId: NCT06288425, orgStudyIdInfo id: SPACE-KIT, briefTitle: Spatial Transcriptomics in Kidney Transplantation, acronym: SPACE-KiT, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-04-03, primaryCompletionDateStruct date: 2030-01-01, completionDateStruct date: 2035-01-01, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Western Sydney Local Health District, class: OTHER, descriptionModule briefSummary: The study is an investigator-led, prospective, longitudinal, observational cohort study.The central hypothesis for this study is that spatial data will reveal new insights to immune cell function and local interactions within the kidney tissue to better predict important clinical outcomes. Investigators aspire to establish a prospective, longitudinal cohort to improve the diagnosis and management of kidney transplant rejection using precision pathology.By utilising new spatial technologies, the investigators aim to:* Derive a spatially resolved transcriptomic signature of kidney transplant rejection subtypes* Derive accurate transcriptomic signatures aligned with key cell types within the transplant kidney* Develop refinements to histological kidney rejection diagnostic and scoring classification* Correlate of spatial and refined biopsy scoring features to clinically important outcomes, conditionsModule conditions: Transplant Complication, conditions: Kidney Injury, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule interventions name: Non interventional, outcomesModule primaryOutcomes measure: Kidney biopsy features, primaryOutcomes measure: Kidney biopsy transcriptomic signature, primaryOutcomes measure: Kidney cell type composition, secondaryOutcomes measure: All cause graft loss, secondaryOutcomes measure: Death censored graft loss (DCGL), secondaryOutcomes measure: Treatment resistant rejection, secondaryOutcomes measure: Delayed graft function (DGF), secondaryOutcomes measure: Biopsy evidence of borderline rejection, secondaryOutcomes measure: Biopsy proven acute rejection, secondaryOutcomes measure: Chronic rejection, secondaryOutcomes measure: Interstitial fibrosis scores (IFTA), secondaryOutcomes measure: BK virus associated nephropathy, secondaryOutcomes measure: Kidney function, secondaryOutcomes measure: Albuminuria, secondaryOutcomes measure: Surrogate end-points, secondaryOutcomes measure: Donor to recipient mismatches, secondaryOutcomes measure: Proteinomic signature, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Westmead Hospital, city: Westmead, state: New South Wales, zip: 2145, country: Australia, geoPoint lat: -33.80383, lon: 150.98768, hasResults: False
protocolSection identificationModule nctId: NCT06288399, orgStudyIdInfo id: DAS-7688, secondaryIdInfos id: U1111-1292-7248, type: OTHER, domain: World Health Organization (WHO), briefTitle: Prevalence and Economic Burden of Obesity-related Comorbidities in the Gulf Region: A Retrospective, Observational Study, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2023-12-21, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Novo Nordisk A/S, class: INDUSTRY, descriptionModule briefSummary: The aim of this study is to assess the annual prevalence of ORCs among adult people with obesity in the real-world clinical setting across the Gulf region. In addition, the study will describe the annual HCRU and associated costs of obesity and ORCs, describe the demographics and clinical characteristics of adult people with obesity, as well as estimate the annual incidence and point prevalence of the ORCs among adult people with obesity., conditionsModule conditions: Obesity, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1322, type: ESTIMATED, armsInterventionsModule interventions name: No treatment given, outcomesModule primaryOutcomes measure: Proportion of Obesity Related Comorbidities (ORC, existing/newly diagnosed) among adult people with obesity (BMI above or equal to 30 kg/m2) over a period of 12 months across the Gulf region in primary and secondary hospitals as well as obesity clinics, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Farwaniya Hospital, city: Farwaniya, zip: 85000, country: Kuwait, locations facility: Al-Adan Hospital, city: Hadiya, zip: 52700, country: Kuwait, locations facility: Al-Amiri Hospital, city: Kuwait City, zip: 13001, country: Kuwait, geoPoint lat: 29.36972, lon: 47.97833, locations facility: Novo Nordisk Investigational Site, city: Kuwait, zip: 12030, country: Kuwait, geoPoint lat: 29.36972, lon: 47.97833, locations facility: National Diabetes and Endocrine Center, city: Muscat, zip: 113, country: Oman, geoPoint lat: 23.58413, lon: 58.40778, locations facility: Samail Polyclinic, city: Samail, zip: 620, country: Oman, geoPoint lat: 23.3, lon: 57.98333, locations facility: Hamad General Hospital, city: Doha, zip: 122104, country: Qatar, geoPoint lat: 25.28545, lon: 51.53096, locations facility: PHCC, city: Doha, zip: 122104, country: Qatar, geoPoint lat: 25.28545, lon: 51.53096, hasResults: False
protocolSection identificationModule nctId: NCT06288386, orgStudyIdInfo id: 2024-ATTACHMENTS, briefTitle: Influence of Different Nanohybrid Flowable Composite Resin on Shear Bond Strength and Dimensional Changes of Invisalign Attachments After 6 Months of Brushing, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-03-04, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2025-02, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: University of Pavia, class: OTHER, descriptionModule briefSummary: The present study will be a single-center, split-mouth, randomized controlled clinical trial. Patients undergoing orthodontic treatment with Invisalign aligners will be enrolled after signing the informed consent. Two different flowable composite resins will be evaluated for the performing of attachments using a split-mouth design:* group A: Filtek Supreme Flow (3M Unitek, Monrovia, Calif)* group B: Grandioso Heavy Flow (VOCO GmbH, Cuxhaven Germany)Digital impressions with iTero intraoral scanner will be performed; digital impressions will be performed after 3 months (T1) and 6 months (T2) from the baseline.Digital scans will be used to assess any changes in shape and volume of the attachments per each different time frame. Each tooth will be separated from the others and superimpositions of the single tooth will be performed with ZEISS Inspect software.After attachments placement, the clinicians will be asked to answer, on a scale from 1 to 10, to this questionnaire's questions about the two different flowable composites; each question is repeated for each composite resin.Type of brushing (with manual or electric toothbrush) and hand of brushing will be recorded., conditionsModule conditions: Malocclusion, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Split-mouth design, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: GrandioSO Heavy Flow, interventions name: Filtek Z350XT Flowable, outcomesModule primaryOutcomes measure: Changes in the volume of attachments, primaryOutcomes measure: Attachments failure rate, primaryOutcomes measure: Type of brushing, primaryOutcomes measure: Change in questionnaire's answers, primaryOutcomes measure: Hand of brushing, eligibilityModule sex: ALL, minimumAge: 14 Years, maximumAge: 70 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Unit of Orthodontics and Pediatric Dentistry - Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Pediatrics - University of Pavia, city: Pavia, state: Lombardy, zip: 27100, country: Italy, geoPoint lat: 45.19205, lon: 9.15917, hasResults: False
protocolSection identificationModule nctId: NCT06288360, orgStudyIdInfo id: NACI-CERV-002, briefTitle: Neoadjuvant Immunochemotherapy in PD-L1-negative LACC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2030-12-12, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Tongji Hospital, class: OTHER, collaborators name: Southwest Hospital, China, collaborators name: Women Hospital, School of Medicine, Zhejiang University, collaborators name: Anhui Provincial Cancer Hospital, collaborators name: Sichuan Cancer Hospital and Research Institute, collaborators name: Gansu Provincial Maternal and Child Health Care Hospital, collaborators name: Beijing Friendship Hospital, collaborators name: Tianjin Medical University General Hospital, collaborators name: Xiangya Hospital of Central South University, collaborators name: West China Second University Hospital, collaborators name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, collaborators name: Zhejiang Cancer Hospital, collaborators name: Shengjing Hospital, collaborators name: Qilu Hospital of Shandong University, descriptionModule briefSummary: This is a multicenter, prospective, single-arm, phase 2 clinical trial designed to evaluate the therapeutic efficacy of the NACI (neoadjuvant chemotherapy plus Camrelizumab) for PD-L1-negative locally advanced cervical cancer., conditionsModule conditions: Cervical Cancer, conditions: Locally Advanced Cervical Cancer, conditions: PD-L1 Negative, conditions: Neoadjuvant Chemoimmunotherapy, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Camrelizumab, interventions name: Paclitaxel-albumin, interventions name: Cisplatin, interventions name: radical surgery, outcomesModule primaryOutcomes measure: Pathologic complete response, secondaryOutcomes measure: Surgical Complications, secondaryOutcomes measure: Objective response rate, secondaryOutcomes measure: Positive surgical margin rate, secondaryOutcomes measure: event-free survival, secondaryOutcomes measure: overall survival, secondaryOutcomes measure: adverse event, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, city: Wuhan, state: Hubei, zip: 430030, country: China, contacts name: Jing Chen, role: CONTACT, phone: 086-027-8362, email: chenjing3223@126.com, contacts name: Kezhen Li, role: PRINCIPAL_INVESTIGATOR, contacts name: Gang Chen, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.58333, lon: 114.26667, hasResults: False
protocolSection identificationModule nctId: NCT06288334, orgStudyIdInfo id: PUTH PD_V 1.2, briefTitle: Exploration of the Optimal Dosage of Cetirizine in the Treatment of Allergic Diseases in Chinese Children, statusModule overallStatus: RECRUITING, startDateStruct date: 2020-08-06, primaryCompletionDateStruct date: 2024-03-31, completionDateStruct date: 2024-05-31, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Peking University Third Hospital, class: OTHER, descriptionModule briefSummary: To obtain the pharmacokinetics of cetirizine in Chinese children with allergic disease., conditionsModule conditions: Allergic Disease, conditions: Children, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: 1-3 Cetirizine Pharmacokinetic samples, outcomesModule primaryOutcomes measure: Plasma concentration, eligibilityModule sex: ALL, minimumAge: 6 Months, maximumAge: 16 Years, stdAges: CHILD, contactsLocationsModule locations facility: Peking University Third Hospital, status: RECRUITING, city: Beijing, state: Beijing, zip: 100191, country: China, contacts name: Yafen Li, role: CONTACT, phone: 18222566785, email: liyafen314159@163.com, contacts name: Wei Zhou, role: PRINCIPAL_INVESTIGATOR, contacts name: Wei Liu, role: PRINCIPAL_INVESTIGATOR, contacts name: Dongyang Liu, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06288308, orgStudyIdInfo id: FAR in lupus nephritis (LN), briefTitle: Fibrinogen to Albumin Ratio (FAR) as a Predictive Biomarker for Lupus Nephritis (LN), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2024-11, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: Fibrinogen to Albumin ratio as a predictive biomarker for lupus nephritis (LN), conditionsModule conditions: Lupus Nephritis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: fibronigin to albumin ratio, outcomesModule primaryOutcomes measure: Fibrinogen to Albumin ratio as a predictive biomarker for lupus nephritis (LN), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06288295, orgStudyIdInfo id: Etude SCORDOM, briefTitle: Retrospective Study on Data Aiming to Establish a Prediction Score for Return Home at the Time of Admission to a Multidisciplinary Medical Department (SCORDOM, acronym: SCORDOM, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-10-01, primaryCompletionDateStruct date: 2023-02-28, completionDateStruct date: 2023-02-28, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Elsan, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to define clinical, biological and socio-cultural criteria, from the very first days of hospitalization on the multidisciplinary medicine department, to guide the patient's discharge from hospital (return to home when discharged from hospital).The data collected will be those contained in the medical records of patients over 60 years of age who were admitted to the multidisciplinary medical department between October 2021 and February 2022 and between October 2022 and February 2023.This study also aims at developing and validating a predictive score of orientation at the end of hospitalisation.Participants are patients previously hospitalized. They will be informed about the study by post and will be able to object to the use of his or her data., conditionsModule conditions: Continuity of Patient Care, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 600, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: Number of patients with a return to home after hospitalization and with similar clinical parameters, similar age category, similar pathology and similar biological parameters, secondaryOutcomes measure: Number of patients with a return to home after hospitalization and with similar clinical parameters, similar age category, similar pathology and similar biological parameters, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hôpital Privé Nancy Lorraine, city: Nancy, zip: 54000, country: France, geoPoint lat: 48.68439, lon: 6.18496, hasResults: False